コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ncer and represents the second most frequent hematologic malignancy.
2 B-cell lymphoma (BCL) is the most common hematologic malignancy.
3 ding and surveillance for the development of hematologic malignancy.
4 frailty and its relevance for patients with hematologic malignancy.
5 coccus (VRE) is an important complication of hematologic malignancy.
6 atch) and survival after transplantation for hematologic malignancy.
7 icts the aggressive clinical outcome of this hematologic malignancy.
8 e care unit (ICU) admission in patients with hematologic malignancy.
9 to investigate differences based on type of hematologic malignancy.
10 uction and expansion of T cells for treating hematologic malignancies.
11 of therapeutic agents, active in a number of hematologic malignancies.
12 ed on the surface of cancer cells in several hematologic malignancies.
13 t can personalize care for older adults with hematologic malignancies.
14 t cells have an increased oxidative state in hematologic malignancies.
15 lity of care for older adults diagnosed with hematologic malignancies.
16 sis to facilitate the automated diagnosis of hematologic malignancies.
17 n approaches for multiple myelomas and other hematologic malignancies.
18 p, for expediting therapeutic innovations in hematologic malignancies.
19 genes associated with an increased risk for hematologic malignancies.
20 equent cytogenetic abnormalities detected in hematologic malignancies.
21 h are in clinical use or clinical trials for hematologic malignancies.
22 or (CAR) T cells are a promising therapy for hematologic malignancies.
23 r pathways and candidate drug targets across hematologic malignancies.
24 28-day cycles, in patients with mutant-IDH2 hematologic malignancies.
25 Blood transfusion is fundamental in managing hematologic malignancies.
26 risk of developing AML and CML but no other hematologic malignancies.
27 advances have been made in various areas of hematologic malignancies.
28 therapeutic target for the treatment of non-hematologic malignancies.
29 ent of patients affected by diverse forms of hematologic malignancies.
30 ation (BMT) is used with curative intent for hematologic malignancies.
31 eased significantly over time, especially in hematologic malignancies.
32 might be an attractive new approach to treat hematologic malignancies.
33 ranslocations are a genomic hallmark of many hematologic malignancies.
34 ociated with a higher risk of early death in hematologic malignancies.
35 on changes implicated in the pathogenesis of hematologic malignancies.
36 ved HBV infection receiving chemotherapy for hematologic malignancies.
37 ly produce positive results in patients with hematologic malignancies.
38 y of duvelisib in 210 patients with advanced hematologic malignancies.
39 oved for the treatment of different types of hematologic malignancies.
40 drug response in 86 patients with refractory hematologic malignancies.
41 nce, survival, and outcomes in patients with hematologic malignancies.
42 tification of novel treatment strategies for hematologic malignancies.
43 in personalized management of patients with hematologic malignancies.
44 own about these disparities in patients with hematologic malignancies.
45 linical relevance of CH in patients with non-hematologic malignancies.
46 actors have emerged as a hallmark of several hematologic malignancies.
47 Some are associated with predisposition to hematologic malignancies.
48 hich -DNMT3A- is frequently mutated in human hematologic malignancies.
49 f malignancies arising in donors including 3 hematologic malignancies.
50 CAR-T cell therapy is effective for hematologic malignancies.
51 or in combination, in both solid tumors and hematologic malignancies.
52 ay increase treatment options for aggressive hematologic malignancies.
53 s among the most frequently mutated genes in hematologic malignancies.
54 ection afflicting patients with diabetes and hematologic malignancies.
55 e measures are appropriate for patients with hematologic malignancies.
56 tumors, and similar evidence has emerged in hematologic malignancies.
57 n important role in detection and staging of hematologic malignancies.
58 pecially for CAR T cells that target CD19(+) hematologic malignancies.
59 therapeutically beneficial, particularly for hematologic malignancies.
60 imab vedotin efficacy in other CD30-positive hematologic malignancies.
61 is a promising approach for the treatment of hematologic malignancies.
62 blastic leukemia and lymphoma, but not other hematologic malignancies.
63 AC) demonstrate efficacy in the treatment of hematologic malignancies.
64 r cells, have been clinically translated for hematologic malignancies.
65 progression, but is poorly characterized in hematologic malignancies.
66 ribute to the development and progression of hematologic malignancies.
67 ses, 75 %), with 74 % for solid and 26 % for hematologic malignancies.
68 ons and enhance ACT against solid tumors and hematologic malignancies.
69 m, which has implications for many solid and hematologic malignancies.
70 nd primary cells obtained from patients with hematologic malignancies.
71 be deregulated by a variety of mechanisms in hematologic malignancies.
72 al therapeutic benefit from blocking PPIs in hematologic malignancies.
73 with a wide variety of cancers, particularly hematologic malignancies.
74 to chemotherapy in human cancers, including hematologic malignancies.
75 Tc1-Th1 antitumor effects against high-risk hematologic malignancies.
76 lure, hepatocellular injury, infections, and hematologic malignancies.
77 therapeutic approaches for cancer, including hematologic malignancies.
78 Twenty-seven patients had underlying hematologic malignancies.
79 lmost exclusively evaluated in patients with hematologic malignancies.
80 ed with long-term remission in patients with hematologic malignancies.
81 ICU admission in hospitalized patients with hematologic malignancies.
82 e preferred treatment for many patients with hematologic malignancies.
83 ependence" of Ph+ ALL and, perhaps, of other hematologic malignancies.
84 ic options for single gene disorders and for hematologic malignancies.
85 uppressed patients in contrast to those with hematologic malignancies.
86 nditions, in particular, but not limited to, hematologic malignancies.
87 hort of 15 patients with GCTs and associated hematologic malignancies.
88 ntly consulted for the care of patients with hematologic malignancies.
89 en medically indicated for older adults with hematologic malignancies.
90 promising dual target inhibitor for treating hematologic malignancies.
91 rface markers in order to represent types of hematologic malignancies.
92 notherapy has produced dramatic responses in hematologic malignancies.
93 omised, distributed into solid tumors (122), hematologic malignancies (106), and nonmalignant immunos
95 plantation (CBT) is an effective therapy for hematologic malignancies, acute graft-versus-host diseas
96 ictive strategies are generally supported in hematologic malignancies, acute neurologic injury, and b
97 A significant proportion of patients with hematologic malignancies admitted to hospital are admitt
98 CD19-directed CAR T cell therapies in B cell hematologic malignancies, advances made in understanding
99 ly 35% to 50% of patients otherwise cured of hematologic malignancies after allogeneic hematopoietic
100 22 primary patient samples from a variety of hematologic malignancies against a panel of 48 drug comb
101 s performed of 271 consecutive patients with hematologic malignancies, age 50 to 75 years, who receiv
102 hat cancer drug addiction arises also in the hematologic malignancy ALK-positive anaplastic large-cel
103 with patients with solid tumors, those with hematologic malignancies also experience high rates of h
104 ) patients, including 18 (36%) patients with hematologic malignancies and 5 (10%) patients with solid
106 bispecific antibodies (bsAb) show promise in hematologic malignancies and are also being evaluated in
107 and systemic diseases such as B-cell lineage hematologic malignancies and connective tissue disorders
108 hereditary cancer syndromes with associated hematologic malignancies and contribute to clinically ef
110 on worldwide and is associated with numerous hematologic malignancies and epithelial malignancies.
112 d higher rates of spontaneous tumors, mainly hematologic malignancies and hepatocellular adenomas and
113 ntly overexpressed in human solid tumors and hematologic malignancies and is associated with tumor ce
114 ent of patients with relapsed and refractory hematologic malignancies and is increasingly investigate
115 ing them with several cancer types including hematologic malignancies and lung cancers, among others.
116 activation-dampening molecule participate in hematologic malignancies and may serve as a key determin
119 whole-exome and RNA sequencing of these rare hematologic malignancies and present the most complete s
120 l role in the biology of del(20q)-associated hematologic malignancies and revealed a novel molecular
121 remarkable success in treating patients with hematologic malignancies and revitalized the field of ad
123 and tumor models, representing a variety of hematologic malignancies and solid tumor indications.
124 bined with mAbs are highly effective against hematologic malignancies and solid tumors that are typic
125 erapy not only of lymphoma but also in other hematologic malignancies and solid tumors that do not ev
129 ch can impact outcome through progression to hematologic malignancies and through cell-non-autonomous
130 s on hospital mortality of ICU patients with hematologic malignancies and to explore interactions bet
131 ients age 70 years or older who had solid or hematologic malignancies and underwent a geriatric asses
135 examine the survival of patients who have a hematologic malignancy and multiple organ failure admitt
136 ned to study the survival of patients with a hematologic malignancy and organ failure after admission
137 al nonseminomatous GCTs develop an incurable hematologic malignancy and prior data intriguingly sugge
138 lants between January 1995 and July 2013 for hematologic malignancy and survived at least 100 days.
141 fied T cells, describe the extant results in hematologic malignancies, and share our outlook on where
143 aging, confers a risk of evolution to overt hematologic malignancy, and increases all-cause mortalit
144 Multiple myeloma (MM) is a relatively common hematologic malignancy, and up to half of patients with
148 individuals with germ line predisposition to hematologic malignancies are diagnosed with increasing f
152 minate potential (CHIP), was associated with hematologic malignancy as well as ASCVD independently of
153 ncluding during the evaluation of a possible hematologic malignancy, as an incidental discovery durin
154 ) signaling and are used in the treatment of hematologic malignancies, block BCR-mediated lytic induc
155 tor that is currently in clinical trials for hematologic malignancies, both ex vivo and in xenotransp
156 ctivation is most common during treatment of hematologic malignancies but also occurs with chemothera
157 rty-seven individuals had breast cancer or a hematologic malignancy but had not yet initiated their t
158 een successfully applied to the treatment of hematologic malignancies, but faces many challenges in s
159 erapy has been effective in the treatment of hematologic malignancies, but it has shown limited effic
160 or (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid t
161 d T cells has generated exciting outcomes in hematologic malignancies, but its application to solid t
162 plant (allo-HCT) can be curative for certain hematologic malignancies, but the risk of graft-versus-h
163 ave mediated dramatic antitumor responses in hematologic malignancies, but tumor regression has rarel
165 hat should help to advance drug discovery in hematologic malignancies by successful targeting of new
167 extracranial embryonal tumors, brain tumors, hematologic malignancies, carcinomas, and gonadal tumors
168 Primary myelofibrosis (PMF) is a clonal hematologic malignancy characterized by BM fibrosis, ext
170 Acute myeloid leukemia (AML) is a deadly hematologic malignancy characterized by the uncontrolled
171 from the IARC added details for prostate and hematologic malignancies, classifying the evidence as su
172 orted outcomes in all survivors of childhood hematologic malignancies correlated with the presence of
176 and are often activated in solid tumors and hematologic malignancies due to intratumoral hypoxia and
177 entially curative treatment for a variety of hematologic malignancies due to the well-recognized graf
179 monstrated tremendous success in eradicating hematologic malignancies (e.g., CD19 CARs in leukemias).
181 ical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinica
182 Multiple myeloma, the second most common hematologic malignancy, frequently relapses because of c
186 nt of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and
187 inical trials in patients with mIDH advanced hematologic malignancies have demonstrated compelling cl
188 ues report that adult survivors of pediatric hematologic malignancies have high symptom prevalence an
189 tigen receptor (CAR) T cells targeting CD19+ hematologic malignancies have rapidly emerged as a promi
191 clinical trial of PD-1 blockade for relapsed hematologic malignancies (HMs) after alloHCT (NCT0182250
192 germ cell tumors (GCTs) in men develop into hematologic malignancies; however, the clonal origins of
193 , and lower risks were noted with underlying hematologic malignancy (HR, 0.29; 95% CI, 0.09-0.98; P =
195 large-scale genomic studies in patients with hematologic malignancies identified recurrent somatic al
197 as (B-NHL) represent the most common type of hematologic malignancies in the Western hemisphere.
198 ominant transmission of thrombocytopenia and hematologic malignancy in three unrelated kindreds, defi
199 ated with worse survival in most subtypes of hematologic malignancies, in a dose-response fashion.
200 T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR
202 r alpha subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemi
203 ibits potent antileukemic effects on several hematologic malignancies including chronic myeloid leuke
204 currently also under investigation in other hematologic malignancies, including acute lymphoblastic
205 ve uncovered a spectrum of mutations in many hematologic malignancies, including acute myeloid leukem
206 Managing these patients with hereditary hematologic malignancies, including familial leukemia, r
207 ation of variants associated with hereditary hematologic malignancies, including the importance of an
208 of 3 approaches to molecular diagnostics in hematologic malignancies: indication-specific single gen
210 Diagnosis of an inherited predisposition to hematologic malignancy informs choice of therapy, risk o
211 ical syndrome, distinct from de novo GCTs or hematologic malignancies, initiated by an ancestral prec
216 gen receptor (CAR)-modified T cells to treat hematologic malignancies is transforming cancer care for
217 C8 (176-406 MBq) into 52 adult patients with hematologic malignancies (lymphoma, multiple myeloma, ac
218 ons for prepubertal children, and women with hematologic malignancies may not be eligible for standar
220 ancies were solid tumors (n = 362; 17.6%) or hematologic malignancies (n = 1,700; 82.4%), including a
221 4905 1-year survivors of allogeneic HCT for hematologic malignancies (N = 4500) or nonmalignant diso
222 lyzed 9,544 transcriptomes from more than 30 hematologic malignancies, normal blood cell types, and c
224 factors were associated with ICU admission: hematologic malignancy (odds ratio, 1.51; 95% CI, 1.26-1
225 Multiple myeloma (MM) is an age-related hematologic malignancy of clonal bone marrow plasma cell
226 n HSCs invariably lead to the development of hematologic malignancies or bone marrow failure syndrome
227 ctive prophylaxis in high-risk patients with hematologic malignancies or hematopoietic cell transplan
228 ddress platelet transfusion in patients with hematologic malignancies or solid tumors or in those who
229 hom 317 (84.7%) were receiving treatment for hematologic malignancies or solid tumors, at 28 intensiv
230 disease due to EV-D68 in adult patients with hematologic malignancy or undergoing hematopoietic cell
231 y produced TPO (a microenvironment factor in hematologic malignancies) or c-MPL-targeted pharmacologi
232 PDCN) is an aggressive and largely incurable hematologic malignancy originating from plasmacytoid den
233 ntified in families with additional types of hematologic malignancies, our group screened two cohorts
236 n oncoproteins are observed in a spectrum of hematologic malignancies, particularly pediatric leukemi
237 vasive fungal infections (bIFIs) among adult hematologic malignancy patients and HCT recipients who r
238 influence of the microbiome on the health of hematologic malignancy patients have concentrated on the
239 influence of the microbiome on the health of hematologic malignancy patients have concentrated on the
240 entical BMT with PTCy, 372 consecutive adult hematologic malignancy patients who underwent this proce
242 ome inhibitors, and to demonstrate that many hematologic malignancies predominantly express immunopro
243 clinical activity in relapsed and refractory hematologic malignancies, primarily acute lymphoblastic
246 l-life tolerability data in 50 patients with hematologic malignancy receiving >=6 months of ISA.
247 covered critical effects of SRSF2 mutants in hematologic malignancies, reflecting the regulation at m
250 fferent centers that evaluated patients with hematologic malignancies requiring HCT who were randomly
251 ial platelet disorder with predisposition to hematologic malignancies (RUNX1-FPD, FPD/AML, FPDMM); ~4
252 investigate the risk and outcomes of second hematologic malignancies (SHMs) in a population-based co
253 d as a candidate for clinical development in hematologic malignancies, solid tumors, and gliomas with
254 t-years and were highest in HCT, followed by hematologic malignancies, SOT, and solid tumor malignanc
255 t-years and were highest in HCT, followed by hematologic malignancies, SOT, solid tumor malignancies,
258 rived acute myeloid leukemia (AML) and other hematologic malignancies such as myelofibrosis (MF) in m
259 ed responses in multiple diseases, including hematologic malignancies, such as Hodgkin lymphoma.
260 The recognition that patients with inherited hematologic malignancy syndromes may present without cla
261 yndrome was not more frequently related with hematologic malignancies than classic neutrophilic Sweet
262 syndrome is more frequently associated with hematologic malignancies than classic Sweet syndrome.
263 R) T cells can produce durable remissions in hematologic malignancies that are not responsive to stan
264 c leukemia (T-ALL) is a highly proliferative hematologic malignancy that results from the transformat
265 suggest that in contrast to the findings in hematologic malignancies, the adaptor protein LNK acts a
266 s at a single institution undergoing HCT for hematologic malignancy, the use of inpatient palliative
267 for treatment of various hematologic and non-hematologic malignancies, there is essentially no inform
268 emonstrated considerable success in treating hematologic malignancies, they have simultaneously been
269 D19 CARs relate to greater susceptibility of hematologic malignancies to CAR therapies, or superior f
270 rds in immunophenotyping cell types found in hematologic malignancies to provide an ontological repre
271 ndition, such as severe infections, solid or hematologic malignancies, trauma, or obstetric calamitie
273 d with cognitive impairment in patients with hematologic malignancies treated with blood or marrow tr
274 risk factors in adult survivors of childhood hematologic malignancies treated with HSCT to those trea
276 (VitD) deficiency is common in patients with hematologic malignancies undergoing allogeneic transplan
277 domized clinical trial among 160 adults with hematologic malignancies undergoing autologous/allogenei
279 erved during this same period in an adjacent hematologic malignancy unit, which followed the same inf
280 although mortality from prostate cancer and hematologic malignancies was noted in the American Cance
281 rmline mutations in children and adults with hematologic malignancies was previously underappreciated
283 ase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 patie
288 residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were frequency matched by demo
289 , but much less immunogenic in patients with hematologic malignancies where the immune system is supp
290 International Consensus Meeting of Prenatal Hematologic Malignancies, which took place in Leuven, Be
291 eukemia (AML) is a genetically heterogeneous hematologic malignancy, which is initiated and driven by
292 thods We randomly assigned 160 patients with hematologic malignancies who underwent autologous or all
294 nts and Methods A total of 681 patients with hematologic malignancy who underwent transplantation in
300 Acute myeloid leukemia (AML) is a deadly hematologic malignancy with poor prognosis, particularly